TD Cowen analyst Ritu Baral has maintained their bullish stance on RLYB stock, giving a Buy rating yesterday.
Ritu Baral has given her Buy rating due to a combination of factors that highlight Rallybio’s promising financial and developmental outlook. The company has a solid cash position of $65.5 million as of the fourth quarter of 2024, which is projected to support operational expenses through the second half of 2026. This financial stability provides a strong foundation for Rallybio’s ongoing and upcoming clinical trials.
Furthermore, Rallybio’s pipeline shows significant potential, particularly with its ‘212 program aimed at preventing alloimmunization and FNAIT in pregnant women. The recent regulatory approvals from the EU and UK for the Phase 2 trial, along with the initiation of dosing in February 2025, underscore the progress and potential of this program. Additionally, the company’s strategic plan to advance ‘212 to Phase 3 trials, contingent on positive interim data, reflects a well-structured development strategy that could lead to substantial advancements in their clinical offerings.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com